A new clinical study has found that an injectable anti-inflammatory drug can help asthma patients clear mucus-clogged airways, improving their breathing and overall quality of life. The drug, dupilumab (brand name Dupixent), significantly reduced mucus buildup and inflammation in patients with moderate to severe asthma, according to findings published on October 27 in the American Journal of Respiratory and Critical Care Medicine.
Targeting One of Asthma’s Most Dangerous Symptoms
Asthma is a chronic respiratory condition affecting more than 25 million people in the United States alone. One of the most dangerous complications of asthma is excessive mucus production, which can block the airways and make breathing extremely difficult.
“In moderate-to-severe asthma, a buildup of mucus in the lungs can obstruct breathing airways to the point where affected patients suffer limited breathing, severe asthma attacks, and even death,” explained Dr. Celeste Porsbjerg, the study’s lead researcher and a professor of severe asthma at Bispebjerg Hospital in Copenhagen, Denmark.
While everyone produces mucus as part of the body’s natural defense system, excessive production can be life-threatening for those with asthma. When inflammation narrows the airways and phlegm accumulates, oxygen flow is restricted—potentially leading to hospitalization or fatal complications.
Dupilumab: A Multi-Purpose Anti-Inflammatory Therapy
Dupilumab is a monoclonal antibody that blocks specific inflammatory proteins, known as interleukins, involved in immune system overactivation. Unlike some other immunosuppressants, dupilumab does not completely suppress immune function; rather, it moderates the body’s inflammatory response to reduce symptoms of chronic disease.
Initially approved in 2017 to treat eczema (atopic dermatitis), dupilumab has since been expanded for use in treating asthma, chronic sinusitis, and chronic obstructive pulmonary disease (COPD). Its success in reducing inflammation across multiple conditions has made it one of the most promising biologic drugs in respiratory medicine.
Clinical Trial Demonstrates Significant Improvements
In the recent double-blind, placebo-controlled trial, researchers enrolled over 100 asthma patients. Participants were randomly assigned to receive an injection of dupilumab or a placebo every two weeks for 24 weeks.
At the start of the study, 67% of patients receiving dupilumab had mucus-plugged airways. After 24 weeks, only 33% remained affected. In contrast, the placebo group saw virtually no improvement—73% of patients had mucus plugging at the beginning, compared with 77% at the end.
Researchers also analyzed breath samples to measure levels of exhaled nitric oxide, a biomarker for airway inflammation. Patients treated with dupilumab showed a significant decline in nitric oxide levels, suggesting that the drug not only clears mucus but also addresses underlying inflammation.
“These outcomes show that dupilumab reduces mucus plugging and airway inflammation in patients with moderate-to-severe asthma as early as four weeks after treatment initiation,” the researchers concluded.
Real-World Impact and Patient Experience
The study findings were welcomed by patient advocacy groups. De De Gardner, chief research officer for the Allergy & Asthma Network, emphasized how mucus buildup affects patients’ quality of life.
“For patients who experience increased mucus production with their asthma flares or attacks, it leads to increased stress and anxiety. Sometimes the stuck mucus can cause gagging because it gets stuck, and they can’t expel it or cough it out,” Gardner said. Although she was not involved in the study, she noted that treatments targeting mucus production could transform asthma management for many patients.
Costs and Considerations
Despite its promising results, dupilumab comes at a steep price. According to Drugs.com, a month’s supply—two 300 mg injections—costs approximately $3,900. The study was funded by Sanofi and Regeneron Pharmaceuticals, the drug’s manufacturers, raising questions about access and affordability.
Nevertheless, for patients with severe asthma who have not responded well to standard treatments, dupilumab may represent a valuable new option to prevent life-threatening mucus obstruction and restore respiratory function.
Conclusion
The findings add to a growing body of evidence supporting the benefits of targeted biologic therapies in managing chronic respiratory diseases. By addressing both airway inflammation and mucus buildup, dupilumab offers new hope to patients struggling with the most dangerous complications of asthma.
While high costs may limit widespread use, ongoing research and potential generic alternatives could one day make this life-saving treatment more accessible to those who need it most.
Related topics:
